Therapeutics development for triplet repeat expansion diseases

Nature Reviews Genetics

Volumn 6, Issue 10, 2005, Pages 756-765

  Di Prospero, Nicholas A ^a   Fischbeck, Kenneth H ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 5 AZA 2' DEOXYCYTIDINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ARYLBUTYRIC ACID DERIVATIVE; BACLOFEN; BUTYRIC ACID; CARBAMAZEPINE; CISPLATIN; CREATINE; DEPSIPEPTIDE; DNA; HEMIN; HISTONE DEACETYLASE INHIBITOR; IDEBENONE; IMIPRAMINE; IRON CHELATING AGENT; MEMANTINE; METABOTROPIC RECEPTOR ANTAGONIST; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NIFEDIPINE; PHENYLACETIC ACID; PHENYTOIN; PRASTERONE SULFATE; PYRIDOXAL ISONICOTINOYLHYDRAZONE; SELENIUM; SUBEROYL ANILIDE HYDROXAMIC ACID; TESTOSTERONE; TOCAINIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

APOPTOSIS; CELL TRANSPLANTATION; CLINICAL EXAMINATION; CLINICAL TRIAL; DEGENERATIVE DISEASE; DOSE RESPONSE; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; EXCITOTOXICITY; FRAGILE X SYNDROME; FRIEDREICH ATAXIA; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; GENETIC CODE; GENETIC DISORDER; GENETIC MODEL; HUMAN; INHERITANCE; MYOTONIC DYSTROPHY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; POLYGLUTAMINE EXPANSION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; REVIEW; SIDE EFFECT; TOXICITY; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; TRINUCLEOTIDE REPEAT;

FRAGILE X SYNDROME; GENE EXPRESSION REGULATION; HEREDODEGENERATIVE DISORDERS, NERVOUS SYSTEM; HUMANS; HUNTINGTON DISEASE; MUTATION; PEPTIDES; TRINUCLEOTIDE REPEATS;

EID: 25844506224     PISSN: 14710056     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrg1690     Document Type: Review

References (134)

1. La Spada, A. R., Wilson, E. M., Lubahn, D. B., Harding, A. E. & Fischbeck, K. H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352, 77-79 (1991).
2. Cummings, C. J. & Zoghbi, H. Y. Fourteen and counting: unraveling trinucleotide repeat diseases. Hum. Mol. Genet. 9, 909-916 (2000).
3. Campuzano, V. et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum. Mol. Genet. 6, 1771-1780 (1997).
4. Wilson, R. B. Frataxin and frataxin deficiency in Friedreich's ataxia. J. Neurol. Sci. 207, 103-105 (2003).
5. Pandolfo, M. Molecular basis of Friedreich ataxia. Mov. Disord. 16, 815-821 (2001).
6. Gillis, J. C., Benefield, P. & McTavish, D. Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. Drugs Aging 5, 133-152 (1994).
7. Rotig, A., Sidi, D., Munnich, A. & Rustin, P. Molecular insights into Friedreich's ataxia and antioxidant-based therapies. Trends Mol. Med. 8, 221-224 (2002). This is a review of the consequences of frataxin loss and the rationale behind antioxidant therapy.
8. Artuch, R. et al. Friedreich's ataxia: idebenone treatment in early stage patients. Neuropediatrics 33, 190-193 (2002).
9. Gutzmann, H. & Hadler, D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. J. Neural Transm. Suppl. 54, 301-310 (1998).
10. Kelso, G. F. et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J. Biol. Chem. 276, 4588-4596 (2001).
11. Jauslin, M. L., Meier, T., Smith, R. A. & Murphy, M. P. Mitochondria-targeted antioxidants protect Friedreich ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J. 17, 1972-1974 (2003).
12. Wardman, P. & Candeias, L. P. Fenton chemistry: an introduction. Radiat. Res. 145, 523-531 (1996).
13. Ponka, P., Borova, J., Neuwirt, J., Fuchs, O. & Necas, E. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim. Biophys. Acta 586, 278-297 (1979).
14. Richardson, D. R., Mouralian, C., Ponka, P. & Becker, E. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. Biochim. Biophys. Acta 1536, 133-140 (2001).
15. Sarsero, J. P. et al. Upregulation of expression from the FRDA genomic locus for the therapy of Friedreich ataxia. J. Gene Med. 5, 72-81 (2003).
16. Ghazizadeh, M. Cisplatin may induce frataxin expression. J. Nippon Med. Sch. 70, 367-371 (2003).
17. Pieretti, M. et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66, 817-822 (1991).
18. Chiurazzi, P., Pomponi, M. G., Willemsen, R., Oostra, B. A. & Neri, G. In vitro reactivation of the FMR1 gene involved in fragile X syndrome. Hum. Mol. Genet. 7, 109-113 (1998).
19. Pascale, E. et al. Modulation of methylation in the FMR1 promoter region after long term treatment with L-carnitine and acetyl-L-carnitine. J. Med. Genet. 40, e76 (2003).
20. Coffee, B., Zhang, F., Warren, S. T. & Reines, D. Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells. Nature Genet. 22, 98-101 (1999).
21. Chiurazzi, P. et al. Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene. Hum. Mol. Genet. 8, 2317-2323 (1999).
22. Nimchinsky, E. A., Oberlander, A. M. & Svoboda, K. Abnormal development of dendritic spines in FMR1 knock-out mice. J. Neurosci. 21, 5139-5146 (2001).
23. Irwin, S. A. et al. Dendritic spine and dendritic field characteristics of layer V pyramidal neurons in the visual cortex of fragile-X knockout mice. Am. J. Med. Genet. 111, 140-146 (2002).
24. Huber, K. M., Gallagher, S. M., Warren, S. T. & Bear, M. F. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl Acad. Sci. USA 99, 7746-7750 (2002).
25. Bear, M. F., Huber, K. M. & Warren, S. T. The mGluR theory of fragile X mental retardation. Trends Neurosci. 27, 370-377 (2004). The theory of excessive metabotropic receptor function in fragile X syndrome.
26. McBride, S. M. et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 45, 753-764 (2005).
27. Meola, G. & Sansone, V. Treatment in myotonia and periodic paralysis. Rev. Neurol. 160, S55-S69 (2004).
28. Fu, Y. H. et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 255, 1256-1258 (1992).
29. Timchenko, N. A. et al. RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J. Biol. Chem. 276, 7820-7826 (2001).
30. Phylactou, L. A., Darrah, C. & Wood, M. J. Ribozyme-mediated trans-splicing of a trinucleotide repeat. Nature Genet. 18, 378-381 (1998).
31. Furuya, H. et al. Some flavonoids and DHEA-S prevent the cis-effect of expanded CTG repeats in a stable PC12 cell transformant. Biochem. Pharmacol. 69, 503-516 (2005).
32. Scalbert, A., Johnson, I. T. & Saltmarsh, M. Polyphenols: antioxidants and beyond. Am. J. Clin. Nutr. 81, S215-S217 (2005).
33. Howitz, K. T. et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191-196 (2003).
34. Parker, J. A. et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nature Genet. 37, 349-350 (2005). This paper describes HDAC (sirtuin family) activation as a means of suppressing polyglutamine toxicity.
35. Reddy, P. H. et al. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nature Genet. 20, 198-202 (1998).
36. Sato, T. et al. Transgenic mice harboring a full-length human mutant DRPLA gene exhibit age-dependent intergenerational and somatic instabilities of CAG repeats comparable with those in DRPLA patients. Hum. Mol. Genet. 8, 99-106 (1999).
37. Katsuno, M. et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35, 843-854 (2002). The authors describe the ligand-dependent toxicity of the mutant androgen receptor in Kennedy disease. This emphasizes the need to understand each polyglutamine disorder in the context of the disease protein's normal function.
38. Reiner, A., Dragatsis, I., Zeitlin, S. & Goldowitz, D. Wild-type huntingtin plays a role in brain development and neuronal survival. Mol. Neurobiol. 28, 259-276 (2003).
39. Cattaneo, E. Dysfunction of wild-type huntingtin in Huntington disease. News Physiol. Sci. 18, 34-37 (2003).
40. Cummings, C. J. et al. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nature Genet. 19, 148-154 (1998).
41. Chai, Y., Koppenhafer, S. L., Shoesmith, S. J., Perez, M. K. & Paulson, H. L. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum. Mol. Genet. 8, 673-682 (1999).
42. Kazemi-Esfarjani, P. & Benzer, S. Genetic suppression of polyglutamine toxicity in Drosophila. Science 287, 1837-1840 (2000).
43. Wyttenbach, A. et al. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc. Natl Acad. Sci. USA 97, 2898-2903 (2000).
44. Sittler, A. et al. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet. 10, 1307-1315 (2001).
45. Heiser, V. et al. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proc. Natl Acad. Sci. USA 99, 16400-16406 (2002). This paper describes the application of high-throughput screening for polyglutamine disorders and shows that inhibitors of aggregation are therapeutic targets.
46. Smith, D. L. et al. Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles. Neurobiol. Dis. 8, 1017-1026 (2001).
47. Sanchez, I., Mahlke, C. & Yuan, J. Pivotal role of oligomerization in expanded polyglutamine neu rodegenerative disorders. Nature 421, 373-379 (2003).
48. Tanaka, M. et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nature Med. 10, 148-154 (2004). The authors discuss an approach to inhibiting protein aggregation using a saccharide-polyglutamine interaction. The safety profile of this chemical seems exceptionally favourable.
49. Khoshnan, A., Ko, J. & Patterson, P. H. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc. Natl Acad. Sci. USA 99, 1002-1007 (2002).
50. Kazantsev, A. et al. A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nature Genet. 30, 367-376 (2002).
51. Kahlem, P., Terre, C., Green, H. & Djian, P. Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: relevance to diseases of the nervous system. Proc. Natl Acad. Sci. USA 93, 14580-14585 (1996).
52. Karpuj, M. V. et al. Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc. Natl Acad. Sci. USA 96, 7388-7393 (1999).
53. Dedeoglu, A. et al. Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci. 22, 8942-8950 (2002).
54. Karpuj, M. V. et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nature Med. 8, 143-149 (2002). This article provides an example of effective treatment after the development of disease manifestations. It also describes activity of the drug outside its pharmacological target.
55. Lesort, M., Lee, M., Tucholski, J. & Johnson, G. V. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J. Biol. Chem. 278, 3825-3830 (2003).
56. Bailey, C. D. & Johnson, G. V. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms. J. Neurochem. 92, 83-92 (2005).
57. Wellington, C. L. & Hayden, M. R. Caspases and neurodegeneration: on the cutting edge of new therapeutic approaches. Clin. Genet. 57, 1-10 (2000).
58. Goldberg, Y. P. et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nature Genet. 13, 442-449 (1996).
59. Wellington, C. L. et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 273, 9158-9167 (1998).
60. Wellington, C. L. et al. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J. Biol. Chem. 275, 19831-19838 (2000).
61. Ona, V. O. et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399, 263-267 (1999).
62. Chen, M. et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nature Med. 6, 797-801 (2000). The authors describe the amelioration of disease manifestations in an HD model with a drug that inhibits caspase.
63. Wang, X. et al. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc. Natl Acad. Sci. USA 100, 10483-10487 (2003).
64. Bonelli, R. M., Hodl, A. K., Hofmann, P. & Kapfhammer, H. P. Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int. Clin. Psychopharmacol. 19, 337-342 (2004).
65. Keene, C. D. et al. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc. Natl Acad. Sci. USA 99, 10671-10676 (2002).
66. Coyle, J. T. & Schwarcz, R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 263, 244-246 (1976).
67. Beal, M. F. et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321, 168-171 (1986).
68. Cepeda, C. et al. NMDA receptor function in mouse models of Huntington disease. J. Neurosci. Res. 66, 525-539 (2001).
69. Zeron, M. M. et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33, 849-860 (2002).
70. Nicniocaill, B., Haraldsson, B., Hansson, O., O'Connor, W. T. & Brundin, P. Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice. Eur. J. Neurosci. 13, 206-210 (2001).
71. Li, J. Y., Plomann, M. & Brundin, P. Huntington's disease: a synaptopathy? Trends Mol. Med. 9, 414-420 (2003).
72. Cha, J. H. et al. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Phil. Trans. R. Soc. Lond. B 354, 981-989 (1999).
73. O'Suilleabhain, P. & Dewey, R. B. Jr. A randomized trial of amantadine in Huntington disease. Arch. Neurol. 60, 996-998 (2003).
74. Lucetti, C. et al. Amantadine in Huntington's disease: open-label video-blinded study. Neurol. Sci. 23, S83-S84 (2002).
75. Verhagen Metman, L. et al. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 59, 694-699 (2002).
76. Murman, D. L. et al. Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease. Neurology 49, 153-161 (1997).
77. Shoulson, I. et al. A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann. Neurol. 25, 252-259 (1989).
78. Kremer, B. et al. Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology 53, 1000-1011 (1999).
79. Seppi, K. et al. Riluzole in Huntington's disease (HD): an open label study with one year follow up. J. Neurol. 248, 866-869 (2001).
80. Li, L. et al. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiol. Aging 24, 1113-1121 (2003).
81. Li, L., Murphy, T. H., Hayden, M. R. & Raymond, L. A. Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. J. Neurophysiol. 92, 2738-2746 (2004).
82. Arning, L. et al. NR2A and NR2B receptor gene variations modify age of onset in Huntington's disease. Neurogenetics 6, 25-28 (2005).
83. Chen, H. S. & Lipton, S. A. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. J. Physiol. 499, 27-46 (1997).
84. Beister, A. et al. The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. J. Neural Transm. 68, S117-S122 (2004).
85. Nicoletti, F. et al. Group-I metabotropic glutamate receptors: hypotheses to explain their dual role in neurotoxicity and neuroprotection. Neuropharmacology 38, 1477-1484 (1999).
86. Schiefer, J. et al. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Res. 1019, 246-254 (2004).
87. 2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J. Neurosci. 22, 1967-1975 (2002).
88. Lastres-Becker, I. et al. Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate. Neuroreport 14, 813-816 (2003).
89. Borlongan, C. V. et al. Systemic 3-nitropropionic acid: behavioral deficits and striatal damage in adult rats. Brain Res. Bull. 36, 549-556 (1995).
90. Gu, M. et al. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39, 385-389 (1996).
91. Browne, S. E. et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41, 646-653 (1997).
92. Beal, M. F. & Ferrante, R. J. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nature Rev. Neurosci. 5, 373-384 (2004). A review of the pathogenesis of HD in the context of mouse models and the efficacy of therapeutic agents tested in these models.
93. Dedeoglu, A. et al. Creatinetherapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J. Neurochem. 85, 1359-1367 (2003).
94. Verbessem, P. et al. Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology 61, 925-930 (2003).
95. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 57, 397-404 (2001).
96. Ranen, N. G. et al. A controlled trial of idebenone in Huntington's disease. Mov. Disord. 11, 549-554 (1996).
97. Okazawa, H. Polyglutamine diseases: a transcription disorder? Cell. Mol. Life Sci. 60, 1427-1439 (2003).
98. McCampbell, A. et al. CREB-binding protein sequestration by expanded polyglutamine. Hum. Mol. Genet. 9, 2197-2202 (2000).
99. Dunah, A. W. et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296, 2238-2243 (2002).
100. Taylor, J. P. et al. Aberrant histone acetylation, altered transcription, and retinal degeneration in a Drosophila model of polyglutamine disease are rescued by CREB-binding protein. Genes Dev. 17, 1463-1468 (2003).
101. Grewal, S. I. & Moazed, D. Heterochromatin and epigenetic control of gene expression. Science 301, 798-802 (2003).
102. Steffan, J. S. et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413, 739-743 (2001). This is a description of reduced acetyltransferase activity and histone acetylation in polyglutamine disease, and how this can be overcome by HDAC inhibitors with consequent amelioration of toxicity.
103. Igarashi, S. et al. Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation. Neuroreport 14, 565-568 (2003).
104. Hockly, E. et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA 100, 2041-2046 (2003).
105. Ferrante, R. J. et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neu rodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23, 9418-9427 (2003). This article discusses the beneficial effects of HDAC inhibitors in an HD mouse model.
106. Gottlicher, M. Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann. Hematol. 83 (Suppl. 1), 91-92 (2004).
107. Burlina, A. B., Ogier, H., Korall, H. & Trefz, F. K. Long-term treatment with sodium phenylbutyrate in ornithine transcar bamylase-deficient patients. Mol. Genet. Metab. 72, 351-355 (2001).
108. Kelly, W. K., O'Connor, O. A. & Marks, P. A. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin. Investig. Drugs 11, 1695-1713 (2002).
109. Brunet, A. et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303, 2011-2015 (2004).
110. Emerich, D. F. et al. Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: rescue and sprouting of degenerating cholinergic basal forebrain neurons. J. Comp. Neurol. 349, 148-164 (1994).
111. Emerich, D. F. et al. Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J. Neurosci. 16, 5168-5181 (1996).
112. Bemelmans, A. P. et al. Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Hum. Gene Ther. 10, 2987-2997 (1999).
113. Perez-Navarro, E., Canudas, A. M., Akerund, P., Alberch, J. & Arenas, E. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease. J. Neurochem. 75, 2190-2199 (2000).
114. McBride, J. L. et al. Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp. Neurol. 181, 213-223 (2003).
115. Kells, A. P. et al. AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol. Ther. 9, 682-688 (2004).
116. Canals, J. M. et al. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci. 24, 7727-7739 (2004).
117. Cepeda, C. et al. Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF. J. Neurosci. Res. 78, 855-867 (2004).
118. Popovic, N., Maingay, M., Kirik, D. & Brundin, P. Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes. Exp. Neurol. 193, 65-74 (2005).
119. Zuccato, C. et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293, 493-498 (2001).
120. Sopher, B. L. et al. Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration. Neuron 41, 687-699 (2004).
121. Bloch, J. et al. Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum. Gene Ther. 15, 968-975 (2004).
122. Dunnett, S. B. et al. Striatal transplantation in a transgenic mouse model of Huntington's disease. Exp. Neurol. 154, 31-40 (1998).
123. van Dellen, A., Deacon, R., York, D., Blakemore, C. & Hannan, A. J. Anterior cingulate cortical transplantation in transgenic Huntington's disease mice. Brain Res. Bull. 56, 313-318 (2001).
124. Freeman, T. B. et al. Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. Proc. Natl Acad. Sci. USA 97, 13877-13882 (2000).
125. Bachoud-Levi, A. C. et al. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 356, 1975-1979 (2000).
126. Gaura, V. et al. Striatal neural grafting improves cortical metabolism in Huntington's disease patients. Brain 127, 65-72 (2004).
127. McBride, J. L. et al. Human neural stem cell transplants improve motor function in a rat model of Huntington's disease. J. Comp. Neurol. 475, 211-219 (2004).
128. Lescaudron, L., Unni, D. & Dunbar, G. L. Autologous adult bone marrow stem cell transplantation in an animal model of huntington's disease: behavioral and morphological outcomes. Int. J. Neurosci. 113, 945-956 (2003).
129. Ende, N. & Chen, R. Human umbilical cord blood cells ameliorate Huntington's disease in transgenic mice. J. Med. 32, 231-240 (2001).
130. Yamamoto, A., Lucas, J. J. & Hen, R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101, 57-66 (2000). The authors show that blockade of expression of the mutant protein leads to a disappearance of inclusions and a reversal of the behavioural phenotype. This indicates that continuous expression of the mutant protein is necessary for the disease.
131. Caplen, N. J. et al. Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference. Hum. Mol. Genet. 11, 175-184 (2002).
132. Xia, H. et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nature Med. 10, 816-820 (2004). A discussion of in vivo use of RNAi as a potential therapy for dominant neurodegenerative disorders.
133. Harper, S. Q. et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl Acad. Sci. USA 102, 5820-5825 (2005). This paper shows that RNAi can accomplish disease allele-specific silencing in vivo.
134. Ravina, B. M. et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 60, 1234-1240 (2003).